Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.32 |
| ▸ | NMT2 | O60551 | 1/20 | 0.32 |
| ▸ | NMT1 | P30419 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.31 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
| ▸ | FURIN | P09958 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25132732 | 0.89 | KDM4E (0.35) | ITGB3ITGA2BKDM4EALDH1A1 | |
| SCHEMBL19062769 | 0.88 | OPRK1 (0.33) | OPRK1ITGB3ITGA2BNMT2NMT1 | |
| SCHEMBL24239548 | 0.88 | OPRK1 (0.33) | OPRK1ITGB3ITGA2BNMT2NMT1 | |
| SCHEMBL19700526 | 0.87 | MMP3 (0.38) | OPRK1ITGB3ITGA2BSIRT6SIRT1 | |
| SCHEMBL21902132 | 0.83 | OPRK1 (0.31) | OPRK1ITGB3ITGA2B | |
| SCHEMBL21154982 | 0.83 | ITGB3 (0.32) | OPRK1ITGB3ITGA2B | |
| SCHEMBL24220950 | 0.82 | NMT2 (0.32) | ITGB3ITGA2BNMT2NMT1 | |
| SCHEMBL18929779 | 0.81 | OPRK1 (0.30) | OPRK1 | |
| SCHEMBL24239560 | 0.79 | KISS1R (0.36) | OPRK1ITGB3ITGA2BKDM4EALDH1A1 | |
| SCHEMBL16248631 | 0.79 | KDM4E (0.35) | ITGB3ITGA2BKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200270609-A1 | Single-Stranded RNAI Oligonucleotides Targeting APOC-III | IONIS PHARMACEUTICALS, INC. (US) | 2020-08-27 | — | — | US | disclosed |
| US-20200157548-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2020-05-21 | — | — | US | disclosed |
| US-20200056185-A1 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2020-02-20 | — | — | US | disclosed |
| US-9932581-B2 | Compositions and methods for modulating apolipoprotein C-III expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157548-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | SI, FABP2, GNE | OPRK1 843/4885ITGB3 278/4885ITGA2B 346/4885 |
| US-20200270609-A1 | Single-Stranded RNAI Oligonucleotides Targeting APOC-III | APOB, APOL1, RBM3 | OPRK1 2601/4885ITGB3 645/4885ITGA2B 1105/4885 |
| US-20200056185-A1 | COMPOSITIONS AND METHODS FOR MODULATING PKK EXPRESSION | GCKR, PKM, PKLR | OPRK1 444/4885ITGB3 2390/4885ITGA2B 2582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.